Global practice and challenges in the diagnosis and management of disseminated intravascular coagulation: communication from the ISTH SSC Subcommittee on Disseminated Intravascular Coagulation Theresa U. Nwagha, Omar I. Hajjaj, Jerrold H. Levy, Hunter Moore, Daniel O'Reilly, Julie Helms, Yutaka Umemura, Toshiaki Iba, Ecaterina Scarlatescu, Maha Othman Journal of Thrombosis and Haemostasis, 2026 BACKGROUND: Despite the global burden of disseminated intravascular coagulation (DIC) and decades of scoring system development, no international assessment has evaluated current global practices among clinicians. OBJECTIVES: To describe international diagnostic and treatment practices for DIC, identify barriers, and examine differences across country income levels. METHODS: The International Society on Thrombosis and Haemostasis (ISTH) Scientific Standardization Subcommittee on DIC conducted an international survey (March 2024 to February 2025) to assess global diagnostic and treatment practices. Analysis was stratified by country income level based on World Bank classifications. RESULTS: A total of 153 clinicians from 27 countries completed the survey, with most respondents from high-income countries (64%). The most suggestive clinical features of DIC were bleeding (89%), petechiae (77%), and shock (63%). Standard laboratory tests, such as platelet count (93%), prothrombin time/international normalized ratio (85%), fibrinogen (78%), and D-dimer (76%), were commonly used; however, respondents from middle-income countries had reduced access to fibrinogen testing, serial monitoring, and advanced diagnostics. Only 28% of clinicians used a formal DIC scoring system (ISTH 21%; sepsis-induced coagulopathy 14%), despite 76% reporting familiarity with the ISTH definition. First-line management relied primarily on fresh-frozen plasma (65%), platelets (38%), and cryoprecipitate (32%), whereas middle-income clinicians more frequently used whole blood and less frequently specialized factor concentrates. Major challenges in the diagnosis and management of DIC included diagnostic uncertainty due to variable underlying disorders (59%) and a heterogeneous clinical presentation (47%). Resource limitations, including restricted laboratory testing (57%), inadequate transfusion supplies (54%), and insufficient critical care support (38%), were more frequent challenges in middle-income countries (P < .001 for all comparisons). CONCLUSION: Despite strong global awareness, major gaps persist between recommended and real-world DIC practice, particularly in resource-limited settings. Efforts to expand access to diagnostics, strengthen transfusion and critical care networks, and support guideline-based management are needed.
Machine Learning in Venous Thromboembolism-Why and What Next? Gerard Gurumurthy, Filip Kisiel, Lianna Reynolds, Will Thomas, Maha Othman, Deepa J. Arachchillage, Jecko Thachil Seminars in Thrombosis and Hemostasis, 2026 Venous thromboembolism (VTE) remains a leading cause of cardiovascular morbidity and mortality, despite advances in imaging and anticoagulation. VTE arises from diverse and overlapping risk factors, such as inherited thrombophilia, immobility, malignancy, surgery or trauma, pregnancy, hormonal therapy, obesity, chronic medical conditions (e.g., heart failure, inflammatory disease), and advancing age. Clinicians, therefore, face challenges in balancing the benefits of thromboprophylaxis against the bleeding risk. Existing clinical risk scores often exhibit only modest discrimination and calibration across heterogeneous patient populations. Machine learning (ML) has emerged as a promising tool to address these limitations. In imaging, convolutional neural networks and hybrid algorithms can detect VTE on CT pulmonary angiography with areas under the curves (AUCs) of 0.85 to 0.96. In surgical cohorts, gradient-boosting models outperform traditional risk scores, achieving AUCs between 0.70 and 0.80 in predicting postoperative VTE. In cancer-associated venous thrombosis, advanced ML models demonstrate AUCs between 0.68 and 0.82. However, concerns about bias and external validation persist. Bleeding risk prediction models remain challenging in extended anticoagulation settings, often matching conventional models. Predicting recurrent VTE using neural networks showed AUCs of 0.93 to 0.99 in initial studies. However, these lack transparency and prospective validation. Most ML models suffer from limited external validation, “black box” algorithms, and integration hurdles within clinical workflows. Future efforts should focus on standardized reporting (e.g., Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis [TRIPOD]-ML), transparent model interpretation, prospective impact assessments, and seamless incorporation into electronic health records to realize the full potential of ML in VTE.
Developing an artificial intelligence–generated peptide targeting platelet-type von Willebrand disease Thomas D. D. Kazmirchuk, Jiashu Wang, Loredana Bury, Emanuela Falcinelli, Calvin Bradbury-Jost, Anastasiia Koziar, Mustafa Al-gafari, Sarah Takallou, William G. Willmore, Frank Dehne, Paolo Gresele, Maha Othman, Ashkan Golshani Blood Advances, 2026 Platelet-type von Willebrand disease (PT-VWD) refers to a rare bleeding disorder caused by gain-of-function mutations in platelet glycoprotein Ibα (GPIbα). These mutations lead to a hyperactive protein-protein interaction (PPI) with von Willebrand factor (VWF) and pathological platelet aggregation. Counterintuitively, patients with PT-VWD present with a bleeding diathesis as opposed to thrombosis. Despite well-defined genetic etiology, no targeted therapy exists for PT-VWD. Here, we sought to develop a peptide inhibitor that selectively targets the aberrant interaction in PT-VWD. Using the In Silico Protein Synthesizer, we designed and screened 10 000 peptides for predicted affinity and specificity toward GPIbαMet239Val. Functional validation of top-ranked peptides included a combination of in vitro functional assays using GPIbαGly233Val, Met239Val and ex vivo platelet assays from patients with PT-VWD. One peptide, G14, emerged as a potent and selective inhibitor of the GPIbαGly233Val, Met239Val–VWF PPI. Functional assays demonstrated that G14 disrupts this interaction without binding GPIbαWT or VWF alone. The peptide also displays picomolar affinity (6.6 pM) for GPIbαGly233Val, Met239Val. Structural modeling predicted G14 binds the β-switch region of GPIbαGly233Val, Met239Val involving the disease-associated Val239 residue. In platelet-rich plasma from a patient with PT-VWD, G14 selectively inhibited platelet-VWF binding and ristocetin-induced agglutination, with no measurable effect on healthy samples. The G14 peptide appears to be a highly specific inhibitor of the GPIbαGly233Val, Met239Val–VWF interaction, providing proof-of-concept data for therapeutic development in PT-VWD. Furthermore, the protein and platelet specificity of these data suggest that G14 may be a potential diagnostic tool for PT-VWD. The approach highlights the utility of artificial intelligence in targeting disease-specific PPIs with high precision.
Red Blood Cell Biomechanics and Cancer-Associated Thrombosis George Ilbawi, Isabell Kearn, Maha Othman Seminars in Thrombosis and Hemostasis, 2026 Cancer-associated thrombosis (CAT) remains a leading cause of morbidity and mortality in oncology, reflecting the convergence of tumor-driven hypercoagulability, endothelial dysfunction, and venous stasis. While current models of CAT pathogenesis emphasize tumor-derived procoagulant factors, platelets, and leukocytes, the contribution of red blood cell (RBC) biomechanics has received comparatively limited attention. Emerging evidence indicates that both malignancy and cancer-related therapies impair RBC deformability and increase RBC aggregation; alterations that are known to influence blood viscosity, platelet margination, microvascular flow, and clot contraction. Hence, these alterations have been hypothesized to promote thrombosis, supported by evidence of increased thrombosis risk in diseases that primarily affect RBC biomechanics. While cancer-induced alterations in RBC biomechanics and their role in thrombosis are well-described in non-cancerous conditions, the relationship between altered RBC biomechanics and thrombosis in the setting of cancer has not been thoroughly investigated. Accordingly, this review synthesizes the mechanistic and clinical data linking altered RBC biomechanics to thrombus initiation, propagation, and stability, with particular emphasis on their relationship with established cancer-related prothrombotic pathways such as extracellular vesicle release, neutrophil extracellular trap formation, stasis, and oxidative stress. Finally, we critically assess current CAT risk assessment models (RAMs) and discuss the potential role of RBC biomechanical parameters as dynamic, integrative biomarkers to improve thrombosis risk stratification in cancer patients. Advances in automated and standardized rheological technologies may facilitate the clinical translation of RBC biomechanics, offering new opportunities to refine risk prediction and deepen mechanistic understanding of CAT.
Coagulation markers as independent predictors of colorectal cancer aggressiveness Hanaa Ali EL-Sayed, Doaa H. Sakr, Mostafa abdelhakiem, Mohamed Awad Ebrahim, Maha Othman, Hanan Azzam BMC Gastroenterology, 2025 Colorectal cancer (CRC) is frequently associated with thrombosis with thrombotic events, such as deep vein thrombosis or pulmonary embolism, often correlate with poor clinical outcomes. Coagulation markers have been suggested as potential prognostic indicators for CRC severity. However, the relationship with clinicopathological characteristics in CRC remains unclear. This study aims to examine the relationship between routine coagulation markers and clinicopathological characteristics in CRC patients. A retrospective analysis was conducted on 100 patients with confirmed diagnosis of CRC, classified according to the 2018 edition of the American Joint Committee on Cancer Tumor/Node/Metastasis staging system for malignant tumors. Clinicopathological characteristics and routine coagulation tests including prothrombin time, and international normalized ratio, activated partial thromboplastin time, prothrombin activity, thrombin time, fibrinogen, d-dimer, platelet count, were evaluated. Spearman correlation was used to assess correlations with clinicopathological characteristics. Additionally, univariate and multivariate ordinal regression analysis were conducted to detect the independent predictors for CRC aggressiveness. Our data documents several associations between coagulation markers and cancer progression markers. Specifically, positive correlations were identified between fibrinogen and d-dimer levels and each of the following: carcinoembryonic antigen, carbohydrate antigen, tumor stage, node involvement, and metastasis. Regression analysis showed, d-dimer (OR = 1.102, p < 0.001) and fibrinogen (OR = 1.002, p < 0.001) are independent predictors of high-risk CRC cases. Fibrinogen and d-dimer may serve as independent predictive biomarkers for CRC aggression. Their clinical utility could support personalized treatment plans for CRC patients.
International opinion survey on nomenclature for platelet-type von Willebrand disease: communication from the SSC of the ISTH Maha Othman, Michelle Lavin, Renhao Li, Abdelrahman Elsebaie, Ross Baker, Marie Lordkipanidzé, Kathleen Freson, Paolo Gresele, Harvey Weiss, Johnathan Miller, Hoyu Takahashi, Jose Lopez, François Lanza, Jerry Ware, Paquita Nurden, Analia Sánchez Luceros, Suchitra Acharya, Shirin Ravanbod, Will Lester, Gillian Lowe, Jecko Thachil, Said Enayat, Emmanuel Favaloro Journal of Thrombosis and Haemostasis, 2025
Enhancing prediction of thrombosis associated with breast cancer using prechemotherapy hematologic and coagulation characteristics Regan Bucciol, Hannah Parente, Yousra Tera, E. Claire Bunker, Aditi Kini, Brooke E. Wilson, Mihaela Mates, Maha Othman Blood Coagulation and Fibrinolysis, 2025 Introduction The applicability of venous thromboembolism (VTE) risk assessment models (RAMs), to breast cancer (BC) populations remains unclear. We aimed to compare the efficacy of current RAMs and examine the potential of additional hematologic parameters and thromboelastography (TEG); a point of care test, in improving VTE prediction in breast cancer (BC) patients. Methods In this pilot study, female BC patients were recruited before chemotherapy and followed for 6–12 months for VTE. VTE risk was assessed using Khorana score, Vienna CATS, PROTECHT, COMPASS-CAT, New Vienna CATSCORE, MDACC CAT, and hypercoagulability status. TEG and hematologic parameters were analyzed, and a modified RAM was developed. Results Among 47 patients, 5 (10.6%) developed VTE. PROTECHT was the strongest predictor [area under the curve (AUC) = 0.844], followed by Vienna CATS (AUC = 0.781). Adding immature granulocytes and red blood cell count to PROTECHT optimized prediction (AUC = 0.856). Conclusion Incorporating hematologic parameters into PROTECHT may improve VTE risk prediction in BC patients, warranting further evaluation in larger studies.
Thromboelastometry (ROTEM) Assessing Hypercoagulability in Patients Referred for Thrombophilia Screening Mazen Assar, Henning Nilius, Natalie Kearn, Wilma Hopman, Michael Nagler, Maha Othman International Journal of Laboratory Hematology, 2025 IntroductionThrombophilia, a blood coagulation disorder, poses risks of venous thromboembolism (VTE). Coagulation assays may not be sufficient to assess VTE risk and global assays such as Rotational Thromboelastometry (ROTEM) may add valuable information. We investigated ROTEM's capacity to detect hypercoagulability in patients undergoing thrombophilia screening, its potential impact on patient outcomes, and limitations.MethodsComprehensive clinical, laboratory, genetic tests, and ROTEM (EXTEM and INTEM) were conducted for 356 patients referred for thrombophilia screening at an academic hospital outpatient unit. Hypercoagulability was identified as a shorter clot formation time (CFT), larger alpha angle (AA), and greater maximum clot firmness (MCF), and was compared in patients with and without VTE. Statistically this was analyzed using Mann–Whitney U and Chi‐square tests with p < 0.05 considered significant.ResultsAmong 356 patients, 64.6% had previous VTE, with 76.9% experiencing one event, 14.3% recurrent (35.6% unprovoked, 64.4% provoked). 22.5% of patients were on anticoagulation. Those with VTE history exhibited significant alterations in EXTEM and INTEM parameters compared to those without (p < 0.001), showing decreased CFT and increased AA and MCF. However, receiver operating characteristic curves for these variables indicated that none were able to discriminate between those individuals with and without thromboembolic complications.ConclusionROTEM does not appear to be a strong discriminatory test. However, it can detect hypercoagulopathy in patients referred for thrombophilia screening. Abnormal ROTEM may indicate a higher risk for recurrence. However, this can only be determined in prospective cohort studies.
Standardization of definition and management for bleeding disorder of unknown cause: communication from the SSC of the ISTH Ross I. Baker, Philip Choi, Nicola Curry, Johanna Gebhart, Keith Gomez, Yvonne Henskens, Floor Heubel-Moenen, Paula James, Rezan Abdul Kadir, Peter Kouides, Michelle Lavin, Marie Lordkipanidze, Gillian Lowe, Andrew Mumford, Nicola Mutch, Michael Nagler, Maha Othman, Ingrid Pabinger, Robert Sidonio, Will Thomas, James S. O’Donnell Journal of Thrombosis and Haemostasis, 2024
Antithrombotic prophylaxis for surgery-associated venous thromboembolism risk disorders. In patients the SPATA-DVT with inherited Study platelet Francesco Paciullo, Loredana Bury, Patrizia Noris, Emanuela Falcinelli, Federica Melazzini, Sara Orsini, Carlo Zaninetti, Rezan Abdul-Kadir, Deborah Obeng-Tuudah, Paula G. Heller, Ana C. Glembotsky, Fabrizio Fabris, Jose Rivera, Maria Luisa Lozano, Nora Butta, Remi Favier, Ana Rosa Cid, Marc Fouassier, Gian Marco Podda, Cristina Santoro, Elvira Grandone, Yvonne Henskens, Paquita Nurden, Barbara Zieger, Adam Cuker, Katrien Devreese, Alberto Tosetto, Erica De Candia, Arnaud Dupuis, Koji Miyazaki, Maha Othman, Paolo Gresele Haematologica, 2020
Bromelain has paradoxical effects on blood coagulability: a study using thromboelastography Blood Coagulation Fibrinolysis an International Journal in Haemostasis and Thrombosis, 2016
A high-throughput sequencing test for diagnosing inherited bleeding, thrombotic, and platelet disorders Ilenia Simeoni, Jonathan C. Stephens, Fengyuan Hu, Sri V. V. Deevi, Karyn Megy, Tadbir K. Bariana, Claire Lentaigne, Sol Schulman, Suthesh Sivapalaratnam, Minka J. A. Vries, Sarah K. Westbury, Daniel Greene, Sofia Papadia, Marie-Christine Alessi, Antony P. Attwood, Matthias Ballmaier, Gareth Baynam, Emilse Bermejo, Marta Bertoli, Paul F. Bray, Loredana Bury, Marco Cattaneo, Peter Collins, Louise C. Daugherty, Rémi Favier, Deborah L. French, Bruce Furie, Michael Gattens, Manuela Germeshausen, Cedric Ghevaert, Anne C. Goodeve, Jose A. Guerrero, Daniel J. Hampshire, Daniel P. Hart, Johan W. M. Heemskerk, Yvonne M. C. Henskens, Marian Hill, Nancy Hogg, Jennifer D. Jolley, Walter H. Kahr, Anne M. Kelly, Ron Kerr, Myrto Kostadima, Shinji Kunishima, Michele P. Lambert, Ri Liesner, José A. López, Rutendo P. Mapeta, Mary Mathias, Carolyn M. Millar, Amit Nathwani, Marguerite Neerman-Arbez, Alan T. Nurden, Paquita Nurden, Maha Othman, Kathelijne Peerlinck, David J. Perry, Pawan Poudel, Pieter Reitsma, Matthew T. Rondina, Peter A. Smethurst, William Stevenson, Artur Szkotak, Salih Tuna, Christel van Geet, Deborah Whitehorn, David A. Wilcox, Bin Zhang, Shoshana Revel-Vilk, Paolo Gresele, Daniel B. Bellissimo, Christopher J. Penkett, Michael A. Laffan, Andrew D. Mumford, Augusto Rendon, Keith Gomez, Kathleen Freson, Willem H. Ouwehand, Ernest Turro Blood, 2016
"Bleeding in the jungle" Alejandro Arbelaez, Johan Niemann, Robert Freney, Maha Othman, Jonas Emsley, Soma Mohammed, Emmanuel J. Favaloro American Journal of Hematology, 2015
Nitric oxide, coagulation and cancer Benjamin A. Derman, Hau C. Kwaan, Malak Elbatarny, Maha Othman Nitric Oxide and Cancer Pathogenesis and Therapy, 2015
The mutational spectrum of type 1 von Willebrand disease: Results from a Canadian cohort study Paula D. James, Colleen Notley, Carol Hegadorn, Jayne Leggo, Angie Tuttle, Shawn Tinlin, Christine Brown, Chandler Andrews, Andrea Labelle, Yvette Chirinian, Lee O'Brien, Maha Othman, Georges Rivard, Dilys Rapson, Christine Hough, David Lillicrap, for the Association of Hemophilia Clinic Directors of Canada Blood, 2007
Founder von Willebrand factor haplotype associated with type 1 von Willebrand disease Lee A. O'Brien, Paula D. James, Maha Othman, Ergul Berber, Cherie Cameron, Colleen R. P. Notley, Carol A. Hegadorn, Jeffrey J. Sutherland, Christine Hough, Georges E. Rivard, Denise O'Shaunessey, David Lillicrap, the Association of Hemophilia Clinic Directors of Canada Blood, 2003
RECENT SCHOLAR PUBLICATIONS
Red Blood Cell Biomechanics and Cancer-Associated Thrombosis G Ilbawi, I Kearn, M Othman Seminars in Thrombosis and Hemostasis , 2026 2026
Platelet-VWF Interactions: A Novel Alternative Binding Site for GPIbalpha GOF on VWF TD Kazmirchuk, C Bradbury-Jost, A Koziar, J Wang, M Othman, ... INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY 48 , 2026 2026
Erythrocytes and Platelets in Cancer: An Exploratory Study R Bucciol, A Qian, A Zandi, M Othman INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY 48 , 2026 2026
Investigating the Relationship Between Red Blood Cell Biomechanical Properties and Anemia in Cancer Patients Undergoing Chemotherapy D Finnigan, R Bucciol, N Cruickshanks, M Othman INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY 48 , 2026 2026
Using Machine Learning to Examine Correlations Between Syllectometry Parameters: Insights into Red Blood Cell Biomechanics B Dastaran, L Elbatarny, M Othman INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY 48 , 2026 2026
Defining Laboratory Reference Values for Red Blood Cells' Rheological Mechanics using Syllectometry Y Tera, M Yunon, R Bucciol, M Othman INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY 48 , 2026 2026
Global practice and challenges in the diagnosis and management of disseminated intravascular coagulation: communication from the ISTH SSC Subcommittee on Disseminated … TU Nwagha, OI Hajjaj, JH Levy, H Moore, D O'Reilly, J Helms, ... Journal of Thrombosis and Haemostasis , 2026 2026
The role of vaccination in maternal and perinatal outcomes associated with COVID-19 in pregnancy E McClymont, S Blitz, L Forward, S Cole, GD Alton, I Boucoiran, K Cassell, ... JAMA 335 (2), 154-162 , 2026 2026 Citations: 8
Developing an artificial intelligence–generated peptide targeting platelet-type von Willebrand disease TDD Kazmirchuk, J Wang, L Bury, E Falcinelli, C Bradbury-Jost, A Koziar, ... Blood Advances 10 (1), 248-259 , 2026 2026 Citations: 3
VENOUS THROMBOEMBOLISM AMONG PATIENTS WITH OVARIAN CANCER: TOWARD SAFE AND EFFECTIVE THROMBOPHYLAXIS Y Tera, M Yunon, R Bucciol, A Stewart, E Park, R Chehade, G Gray, ... International Journal of Gynecological Cancer 35 (11) , 2025 2025
Prognostic Accuracy of the Khorana and Caprini Thromboembolic Risk Assessment Models in Patients with Gynecological Tumours: A Meta-Analysis A Fu, PA Norman, Y Umemura, A Ahmed, ZAA Hammad, OI Hajjaj, ... Thrombosis Research 254 , 2025 2025
Thromboelastography and Haematologic Parameters for Venous Thromboembolism Prediction in Ovarian Cancer Patients Under Chemotherapy Y Tera, M Yunon, R Bucciol, R Chehade, A Agrawal, M Othman Thrombosis Research 254 , 2025 2025
Coagulation markers as independent predictors of colorectal cancer aggressiveness HA El-Sayed, DH Sakr, M Abdelhakiem, MA Ebrahim, M Othman, ... BMC gastroenterology 25 (1), 634 , 2025 2025 Citations: 1
Optimal Cutoff for the Neutrophil-to-Lymphocyte Ratio as a Tool for Pre-chemotherapy Prognosis Stratification of Breast Cancer Patients A Zandi, A Qian, M Othman Cureus 17 (8) , 2025 2025 Citations: 4
Machine Learning in Venous Thromboembolism–Why and What Next? G Gurumurthy, F Kisiel, L Reynolds, W Thomas, M Othman, ... Seminars in Thrombosis and Hemostasis , 2025 2025 Citations: 7
Mortality, diagnosis, and etiology of disseminated intravascular coagulation—a systematic review and meta-analysis: communication from the ISTH SSC subcommittee on … Y Umemura, E Scarlatescu, TU Nwagha, JH Levy, M Othman, H Moore, ... Journal of Thrombosis and Haemostasis 23 (8), 2663-2679 , 2025 2025 Citations: 11
Enhancing prediction of thrombosis associated with breast cancer using prechemotherapy hematologic and coagulation characteristics R Bucciol, H Parente, Y Tera, EC Bunker, A Kini, BE Wilson, M Mates, ... Blood Coagulation & Fibrinolysis 36 (5), 221-227 , 2025 2025
Updated definition and scoring of disseminated intravascular coagulation in 2025: communication from the ISTH SSC Subcommittee on Disseminated Intravascular Coagulation T Iba, JH Levy, CL Maier, J Helms, Y Umemura, H Moore, M Othman, ... Journal of Thrombosis and Haemostasis 23 (7), 2356-2362 , 2025 2025 Citations: 65
Thromboelastometry (ROTEM) Assessing Hypercoagulability in Patients Referred for Thrombophilia Screening M Assar, H Nilius, N Kearn, W Hopman, M Nagler, M Othman International Journal of Laboratory Hematology 47 (3), 520-528 , 2025 2025 Citations: 4
Deranged balance of hemostasis and fibrinolysis in disseminated intravascular coagulation: assessment and relevance in different clinical settings E Scarlatescu, T Iba, CL Maier, H Moore, M Othman, JM Connors, ... Obstetric Anesthesia Digest 45 (2), 67-68 , 2025 2025 Citations: 10
MOST CITED SCHOLAR PUBLICATIONS
The mutational spectrum of type 1 von Willebrand disease: results from a Canadian cohort study PD James, C Notley, C Hegadorn, J Leggo, A Tuttle, S Tinlin, C Brown, ... Blood 109 (1), 145-154 , 2007 2007 Citations: 439
Adenovirus-induced thrombocytopenia: the role of von Willebrand factor and P-selectin in mediating accelerated platelet clearance M Othman, A Labelle, I Mazzetti, HS Elbatarny, D Lillicrap Blood 109 (7), 2832-2839 , 2007 2007 Citations: 302
Association of SARS-CoV-2 infection during pregnancy with maternal and perinatal outcomes E McClymont, AY Albert, GD Alton, I Boucoiran, E Castillo, DB Fell, ... Jama 327 (20), 1983-1991 , 2022 2022 Citations: 222
A high-throughput sequencing test for diagnosing inherited bleeding, thrombotic, and platelet disorders I Simeoni, JC Stephens, F Hu, SVV Deevi, K Megy, TK Bariana, ... Blood, The Journal of the American Society of Hematology 127 (23), 2791-2803 , 2016 2016 Citations: 211
A new hemophilia carrier nomenclature to define hemophilia in women and girls: communication from the SSC of the ISTH KPM van Galen, R d’Oiron, P James, R Abdul‐Kadir, PA Kouides, ... Journal of Thrombosis and Haemostasis 19 (8), 1883-1887 , 2021 2021 Citations: 201
Standardization of thromboelastography: a report from the TEG‐ROTEM working group M Chitlur, B Sorensen, GE Rivard, G Young, J Ingerslev, M Othman, ... Haemophilia 17 (3), 532-537 , 2011 2011 Citations: 192
Systematic review of viscoelastic testing (TEG/ROTEM) in obstetrics and recommendations from the women's SSC of the ISTH A Amgalan, T Allen, M Othman, HK Ahmadzia Journal of Thrombosis and Haemostasis 18 (8), 1813-1838 , 2020 2020 Citations: 173
Spontaneous pregnancy loss mediated by abnormal maternal inflammation in rats is linked to deficient uteroplacental perfusion SJ Renaud, T Cotechini, JS Quirt, SK Macdonald-Goodfellow, M Othman, ... The Journal of Immunology 186 (3), 1799-1808 , 2011 2011 Citations: 163
DIC in pregnancy–pathophysiology, clinical characteristics, diagnostic scores, and treatments O Erez, M Othman, A Rabinovich, E Leron, F Gotsch, J Thachil Journal of blood medicine, 21-44 , 2022 2022 Citations: 162
Haemostatic and thrombo-embolic complications in pregnant women with COVID-19: a systematic review and critical analysis J Servante, G Swallow, JG Thornton, B Myers, S Munireddy, ... BMC pregnancy and childbirth 21 (1), 108 , 2021 2021 Citations: 159
Hemostatic laboratory derangements in COVID-19 with a focus on platelet count A Amgalan, M Othman Platelets 31 (6), 740-745 , 2020 2020 Citations: 148
Founder von Willebrand factor haplotype associated with type 1 von Willebrand disease LA O'Brien, PD James, M Othman, E Berber, C Cameron, CRP Notley, ... Blood 102 (2), 549-557 , 2003 2003 Citations: 129
Exploring possible mechanisms for COVID‐19 induced thrombocytopenia: Unanswered questions A Amgalan, M Othman Journal of Thrombosis and Haemostasis 18 (6), 1514-1516 , 2020 2020 Citations: 123
Thromboelastography (teg) M Othman, H Kaur Hemostasis and thrombosis: methods and protocols, 533-543 , 2017 2017 Citations: 110
Identification and functional characterization of a novel 27-bp deletion in the macroglycopeptide-coding region of the GPIBA gene resulting in platelet-type von Willebrand disease M Othman, C Notley, FL Lavender, H White, CD Byrne, D Lillicrap, ... Blood 105 (11), 4330-4336 , 2005 2005 Citations: 104
Thromboelastography identifies hypercoagulablilty and predicts thromboembolic complications in patients with prostate cancer M Toukh, DR Siemens, A Black, S Robb, M Leveridge, CH Graham, ... Thrombosis research 133 (1), 88-95 , 2014 2014 Citations: 100
COVID‐19 coagulopathy in pregnancy: Critical review, preliminary recommendations, and ISTH registry—Communication from the ISTH SSC for Women’s Health RA Kadir, T Kobayashi, T Iba, O Erez, J Thachil, S Kazi, AK Malinowski, ... Journal of Thrombosis and Haemostasis 18 (11), 3086-3098 , 2020 2020 Citations: 98
Frequency of platelet type versus type 2B von Willebrand disease A Hamilton, M Ozelo, J Leggo, C Notley, H Brown, JP Frontroth, ... Thrombosis and haemostasis 105 (03), 501-508 , 2011 2011 Citations: 82
Recombinant and plasma-derived factor VIII products induce distinct splenic cytokine microenvironments in hemophilia A mice M Qadura, B Waters, E Burnett, R Chegeni, S Bradshaw, C Hough, ... Blood, The Journal of the American Society of Hematology 114 (4), 871-880 , 2009 2009 Citations: 82
Platelet-type von Willebrand disease: new insights into the molecular pathophysiology of a unique platelet defect M Othman, H Kaur, J Emsley Seminars in thrombosis and hemostasis 39 (06), 663-673 , 2013 2013 Citations: 72
